Overview and Treatment of Opioid-Induced Constipation

References

• . Gatti A, Sabato AF. Management of opioid-induced constipation in cancer patients: focus on methylnaltrexone. Clin Drug Investig. 2012;32(5):293–301
   PubMed Web of Science ®Google Scholar
• . Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106(5):835–842
   PubMed Web of Science ®Google Scholar
• . Boudreau D, Von KM, Rutter CM, . Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf. 2009;18(12):1166–1175
   PubMed Web of Science ®Google Scholar
• . Malchow RJ, Black IH. The evolution of pain management in the critically ill trauma patient: emerging concepts from the global war on terrorism. Crit Care Med. 2008;36( 7 suppl):S346–S357
   Google Scholar
• . Wu CL, Raja SN. Treatment of acute postoperative pain. Lancet. 2011;377(9784):2215–2225
   PubMed Web of Science ®Google Scholar
• . Becker DE. Pain management: part 1: managing acute and postoperative dental pain. Anesth Prog. 2010;57(2):67–79
   PubMedGoogle Scholar
• . Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 2009;10(1):35–42
   PubMed Web of Science ®Google Scholar
• . Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001;182( 5 A suppl):11S–18S
   PubMed Web of Science ®Google Scholar
• . Bagnol D, Mansour A, Akil H, Watson SJ. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 1997;81(2):579–591
   PubMedGoogle Scholar
• . McKay JS, Linaker BD, Turnberg LA. Influence of opiates on ion transport across rabbit ileal mucosa. Gastroenterology. 1981;80(2):279–284
   PubMedGoogle Scholar
• . Fickel J, Bagnol D, Watson SJ, Akil H. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res Mol Brain Res. 1997;46(1–2):1–8
   PubMedGoogle Scholar
• . Philippe D, Chakass D, Thuru X, . Mu opioid receptor expression is increased in inflammatory bowel diseases: implications for homeostatic intestinal inflammation. Gut. 2006;55(6):815–823
   PubMedGoogle Scholar
• . Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept. 2009;155(1–3):11–17
   PubMed Web of Science ®Google Scholar
• . Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF. Novel opioid antagonists for opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2011;20(8):1047–1056
   PubMed Web of Science ®Google Scholar
• . McMillan SC. Assessing and managing opiate-induced constipation in adults with cancer. Cancer Control. 2004;11( 3 suppl):3–9
   PubMedGoogle Scholar
• . Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372–380
   PubMed Web of Science ®Google Scholar
• . McMillan SC, Small BJ. Symptom distress and quality of life in patients with cancer newly admitted to hospice home care. Oncol Nurs Forum. 2002;29(10):1421–1428
   PubMedGoogle Scholar
• . Glare P, Lickiss JN. Unrecognized constipation in patients with advanced cancer: a recipe for therapeutic disaster. J Pain Symptom Manage. 1992;7(6):369–371
   PubMedGoogle Scholar
• . Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181–1187
   PubMed Web of Science ®Google Scholar
• . National Comprehensive Cancer Network Guidelines 2.2012 Panel. NCCN Clinical Practice Guidelines in Oncology: Palliative Care. Version 2.2012. 2012. Fort Washington, PA: National Comprehensive Cancer Network, Inc.; 2012
   Google Scholar
• . Goodheart CR, Leavitt SB. Managing opioid-induced constipation in ambulatory-care patients. http://paintopics.org/pdf/Managing_Opioid-inducedConstipation.pdf. Released August 2006. Accessed December 9, 2012
   Google Scholar
• . Cherny N, Ripamonti C, Pereira J, . Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19(9):2542–2554
   PubMed Web of Science ®Google Scholar
• . Candy B, Jones L, Goodman ML, Drake R, Tookman A. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev. 2011;1:CD003448
   PubMed Web of Science ®Google Scholar
• . Meissner W, Schmidt U, Hartmann M, Kath R, Reinhart K. Oral naloxone reverses opioid-associated constipation. Pain. 2000;84(1):105–109
   PubMed Web of Science ®Google Scholar
• . Baker DE. Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunction. Rev Gastroenterol Disord. 2009;9(3):E84–E93
   Google Scholar
• . Cubist Pharmaceuticals. CB-5945 (bevenopran) fact sheet. http://cubist.com/downloads/CB-5945_Fact_Sheet_122012.pdf. 2012. Accessed February 1, 2013
   Google Scholar
• . Rosow CE, Gomery P, Chen TY, Stefanovich P, Stambler N, Israel R. Reversal of opioid-induced bladder dysfunction by intravenous naloxone and methylnaltrexone. Clin Pharmacol Ther. 2007;82(1):48–53
   PubMedGoogle Scholar
• . Slatkin N, Thomas J, Lipman AG, . Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009;7(1):39–46
   PubMedGoogle Scholar
• . Thomas J, Karver S, Cooney GA, . Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008;358(22):2332–2343
   PubMed Web of Science ®Google Scholar
• . Michna E, Blonsky ER, Schulman S, . Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: a randomized controlled study. J Pain. 2011;12(5):554–562
   PubMed Web of Science ®Google Scholar
• . Slatkin NE, Lynn R, Su C, Wang W, Israel RJ. Characterization of abdominal pain during methylnaltrexone treatment of opioid-induced constipation in advanced illness: a post hoc analysis of two clinical trials. J Pain Symptom Manage. 2011;42(5):754–760
   PubMed Web of Science ®Google Scholar
• . Jansen JP, Lorch D, Langan J, . A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):185–193
   PubMed Web of Science ®Google Scholar
• . Irving G, Penzes J, Ramjattan B, . A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011;12(2):175–184
   PubMed Web of Science ®Google Scholar
• . Adolor Corporation provides update on R&D programs [press release]. Exton, PA: Adolor Corporation; December 18, 2008. http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aMtMyltp.qMc. Accessed February 7, 2013
   Google Scholar
• . Entereg(alvimopan) capsules [package insert]. Lexington, MA: Cubist Pharmaceuticals, Inc.; 2012
   Google Scholar
• . GSK and Adolor announce preliminary results from phase 3 safety study of alvimopan (Entereg/Entrareg) [press release]. London, UK, and Exton, PA: GlaxoSmithKline; April 9, 2007. http://www.gsk.com/media/press-releases/2007/gsk-and-adolor-announce-preliminary-results-from-phase-3-safety-study-of-alvimopan-enteregentrareg.html. Accessed February 1, 2013
   Google Scholar
• . Magge S, Lembo A, Cremonini F. The efficacy of peripherally acting opioid antagonists in opioid-induced constipation: meta-analysis of controlled clinical trials [abstract]. Gastroenterology. 2012;142( suppl 1):S-812
   PubMedGoogle Scholar
• . AstraZeneca announces top-line phase III results from Naloxegol pivotal trials in patients with opioid-induced constipation [press release]. San Francisco, CA: Nektar Therapeutics; November 12, 2012. http://ir.nektar.com/releasedetail.cfm7ReleaseID=720408. Accessed December 9, 2012
   Google Scholar
• . Beattie DT, Vickery R, Armstrong SR, . TD-1211, a potent and peripherally-selective μ-opioid receptor antagonist. Poster presented at: 13th World Congress on Pain; August 29-September 2, 2010; Montréal, Québec, Candada. Poster PW 262
   Google Scholar
• . Vickery R, Yu-Ping L, Schwertschlag U, Singla N, Webster L, Canafax D. TD-1211 demonstrates improvement in bowel movement frequency and Bristol stool scores in a phase 2b study of patients with opioid-induced constipation (OIC). Poster presented at: American College of Gastroenterology 2012 Annual Scientific Meeting; October 23, 2012; Las Vegas, NV. Poster Program no. 36
   Google Scholar
• . www.ClinicalTrials.gov. Safety Study of CB-5945 for the Treatment of Opioid-induced Constipation. NCTO1696643. http://www.clinicaltrials.gov/ct2/show/NCT01696643?term=cb-5945&rank=1. Accessed February 1, 2013
   Google Scholar
• . Singla N, Techner LM, Gabriel K, Mangano R. CB-5945 0.25 mg twice daily is associated with significantly increased spontaneous bowel movement and greater proportion of responders compared with placebo in patients on chronic opioid therapy for noncancer pain. Poster presented at: Digestive Disease Week; May 19–22, 2012; San Diego, CA. Poster Mo2084
   Google Scholar
• . Techner LM, Singla N, Gabriel K, Mangano R. CB-5945 (formerly ADL5945), a potent orally bioavailable peripheral opioid receptor antagonist, improves bowel motility with a low incidence and severity of gastrointestinal adverse effects in a dose-dependent manner; results of 2 phase 2 trials in patients with opioid-induced constipation. Poster presented at: American Pain Society 31st Annual Scientific Meeting; May 16–19, 2012; Honolulu, HI. Poster 434
   Google Scholar
• . Ahmedzai SH, Nauck F, Bar-Sela G, Bosse B, Leyendecker P, Hopp M. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2011;26(1):50–60
   PubMedGoogle Scholar
• . Targin® (oral oxycodone/naloxone prolonged-release tablet) now launching across Europe to control severe chronic pain with significantly reduced risk of opioid-induced constipation [press release]. Cambridge: PR Newswire; January 26, 2009. http://multivu.prnewswire.com/mnr/targin/36704/. Accessed February 7, 2013
   Google Scholar
• . Wong BS, Camilleri M. Lubiprostone for the treatment of opioid-induced bowel dysfunction. Expert Opin Pharmacother. 2011;12(6):983–990
   PubMed Web of Science ®Google Scholar
• . Shire acquires US rights to Resolor® (prucalopride) [press release]. Philadelphia, PA: Shire; January 10, 2012. http://www.shire.com/shire-plc/en/investors/irshirenews?id=553. Accessed February 7, 2013
   Google Scholar
• . Jamal MM, Mareya SM, Woldegeorgis F, Joswick TR, Ueno R. Lubiprostone significantly improves treatment response in non-methadone opioid-induced bowel dysfunction patients with chronic, non-cancer pain: results from a phase 3, randomized, double-blind, placebo-controlled clinical trial. Poster presented at: Digestive Diseases Week 2012; May 19–22, 2012; San Diego, CA. Poster 848a
   Google Scholar
• . Sloots CE, Rykx A, Cools M, Kerstens R, De PM. Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation. Dig Dis Sci. 2010;55(10):2912–2921
   PubMed Web of Science ®Google Scholar